Form 4 for NDRA ENDRA Life Sciences Inc.
Accepted 2026-03-04 00:00:00 ET · period of report 2026-03-02 · accession 0001193125-26-092253 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-04 | 2026-03-02 | NDRA | Tokman Alexander Y | CEO, Dir | A - Grant | $0.00 | +26.9K | 101.9K | +36% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-02 | A | A | 26,921 | $0.00 | 101,926 | D | — | — | (F1) Holdings include unvested restricted stock units ("RSUs"). (F2) Represents RSUs that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 11, 2026. |